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Background: Diffuse large B cell lymphoma (DLBCL) represents the most common histological subtype of primary
gastrointestinal lymphoma and is a heterogeneous group of disease. Prognostic characterization of individual
patients is an essential prerequisite for a proper risk-based therapeutic choice.
Methods: Clinical and pathological prognostic factors were identified, and predictive value of four previously
described prognostic systems were assessed in 101 primary gastrointestinal DLBCL (PG-DLBCL) patients with
localized disease, including Ann Arbor staging with Musshoff modification, International Prognostic Index (IPI),
Lugano classification, and Paris staging system.
Results: Univariate factors correlated with inferior survival time were clinical parameters [age >60 years old,
multiple extranodal/gastrointestinal involvement, elevated serum lactate dehydrogenase and β2-microglobulin,
and decreased serum albumin], as well as pathological parameters (invasion depth beyond serosa, involvement of
regional lymph node or adjacent tissue, Ki-67 index, and Bcl-2 expression). Major independent variables of adverse
outcome indicated by multivariate analysis were multiple gastrointestinal involvement. In patients unfit for
Rituximab but received surgery, radical surgery significantly prolonged the survival time, comparing with alleviative
surgery. Addition of Rituximab could overcome the negative prognostic effect of alleviative surgery. Among the
four prognostic systems, IPI and Lugano classification clearly separated patients into different risk groups. IPI was
able to further stratify the early-stage patients of Lugano classification into groups with distinct prognosis.
Conclusions: Radical surgery might be proposed for the patients unfit for Rituximab treatment, and a combination
of clinical and pathological staging systems was more helpful to predict the disease outcome of PG-DLBCL patients.
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Non-Hodgkin’s lymphoma of the gastrointestinal tract
is the most common extranodal lymphoma, accounting
for 30–40 % of the patients, in which diffuse large B
cell lymphoma (DLBCL) is the most frequent histo-
logical subtype with a variable clinical outcome [1, 2].
Therefore, prognostic characterization of individual
patients is an essential prerequisite for a proper risk-
based therapeutic choice.
Surgery was once the standard procedure or a regular
component of combined treatment modalities in primary
gastrointestinal DLBCL (PG-DLBCL) [3]. The factors in
favor of a surgical approach include the removal of pri-
mary lesions, availability of precise histological classifica-
tion and staging, as well as avoidance of complications
such as perforation or hemorrhage that may occur during
radiotherapy and chemotherapy [4–6]. In the recent years,
opinion has increasingly swung toward non-invasive treat-
ment even for patients with resectable disease, so as to
maintain their quality of life [7–9]. However, the benefit of
a surgical approach remains controversial in the patients
treated with Rituximab and chemotherapy/radiotherapy.
Several staging systems have been developed over the
past decades to improve prognostic stratification of
primary gastrointestinal lymphoma, mainly taking into
account different clinical parameters. The classical Ann
Arbor staging system is adapted for extranodal lymph-
oma, as proposed by Musshoff et al. [10]. International
Prognostic Index (IPI) is originated from patients with
DLBCL that consists of age, performance status, Ann
Arbor stage, serum lactate dehydrogenase (LDH), and
extranodal involvement [11]. Meanwhile, novel scores
have been explored, namely Lugano classification and
Paris staging system [12, 13], which combine clinical fea-
tures with pathological findings of the tumors.
Although both clinical and pathological prognostic sys-
tems were effective in the patient series used to drive
them, their utility needs testing in other patient popula-
tions of PG-DLBCL, particularly in those with accurate
pathological data obtained by a surgical approach. More-
over, direct evaluation and comparison of these systems
are limited in large -scale Chinese patients with localized
disease in the Rituximab era. To address this issue, we
conducted a retrospective analysis of 101 patients followed
up in our Institution over the last 12 years to identify the
main prognostic factors and to compare different staging
systems in the prediction of survival in localized PG-
DLBCL that received a surgical approach.
Methods
Patients
From January 2003 to October 2014, a total of 101
patients of localized PG-DLBCL received a surgical ap-
proach were included in this retrospective study and 49patients who received chemotherapy alone were referred
as control. PG-DLBCL was defined according to Lewin
et al.: patients had to present gastrointestinal symptoms
or predominant lesions in the gastrointestinal tract [14].
Informed consent was obtained from all patients, in
accordance with the regulations of the Shanghai Jiao
Tong University School of Medicine Institutional Re-
view Boards.Diagnosis and staging systems
Pathological diagnosis was established according to the
World Health Organization (WHO) classification [15].
The staging work-up included history and physical exam-
ination, blood cell counts and serum chemistry, bone
marrow aspiration or biopsy, endoscopy of gastrointestinal
tracts, and chest and abdominal tomography scan or
positron emission tomography-computerized tomography
(PET-CT). The stage of lymphoma was assessed following
the guidelines of Ann Arbor staging with Musshoff mo-
dification (Ie1/Ie2/IIe1/IIe2), IPI (low/low–intermediate/
high–intermediate/high-risk), Lugano classification (I/II1/
II2/IIE), and Paris staging system (TxNxMxBx), respect-
ively. The macroscopic type of lymphoma (ulcerative,
diffuse, or massive type), the depth of tumor invasion, as
well as the involvement of regional lymph nodes and adja-
cent structure were determined based on histology of the
resected tumor specimens.Treatment and response
A standard radical gastrectomy is defined as a gastrec-
tomy with D2 lymphadenectomy and resection of Nl
and N2 lymph nodes [16]. Radical surgery for primary
intestinal lymphoma is defined as completely primary
mass resection and regional lymph nodes dissection. As
for the alleviative surgery, the lesions were not com-
pletely resected, which is also called surgical debulking,
including local mass resection (R1–R2), enterostomy,
and simple perforation repair [17, 18].
The patients received a surgical approach, either alone
or followed by chemotherapy (four to six standard dose of
CHOP regimens) or combined with Rituximab (375 mg/
m2). The treatment response was evaluated according to
the WHO response criteria. Complete response (CR) was
defined as no evidence of residual disease, partial response
(PR) with at least 50 % reduction in tumor burden from
the onset of treatment, and stable disease (SD) and pro-
gression disease (PD) with less than 50 % reduction in
tumor burden or disease progression. Assessment of
treatment response was evaluated by clinical follow-up,
radiological, or laboratory studies, as determined by the
clinician. The patients who had stable disease or partial
response received second-line chemotherapy instead of
radiotherapy.
Zhang et al. World Journal of Surgical Oncology  (2015) 13:246 Page 3 of 8Statistic analysis
Overall survival (OS) was measured from the date of
diagnosis to the date of death or the last follow-up.
Relapse-free survival (RFS) was calculated from the
date of diagnosis to the date of disease relapse or the
last follow-up. Survival functions were estimated using
the Kaplan-Meier method and compared by the log-
rank test. Chi-square was used for comparison of the
clinical data of the patients with different treatments.
Multivariate survival analysis was performed using Cox
regression model. Significant variables in the univariate
analysis were selected as variables in the multivariate
analysis for survival. P < 0.05 was considered statisti-
cally significant. All statistical analyses were evaluated
using Statistical Package for the Social Sciences (SPSS)
18.0 software (SPSS Inc., Chicago, IL).
Results
Clinical characteristics
As shown in Table 1, 64 of the 101 patients (63 %) were
<=60 years old and the median age was 57 years (ranged
18 to 82 years). There were 57 male and 44 female
patients. All the patients presented gastrointestinal
symptoms such as abdominal discomfort (67 cases,
66 %), severe gastrointestinal bleeding (16 cases, 16 %),Table 1 Clinicopathological characteristics of patients with localized
Characteristics N (%)
Age (years) <=60 64 (63)
>60 37 (37)
Sex Male 57 (56)
Female 44 (44)
B symptoms No 57 (56)
Yes 44 (44)
Extranodal involvement Single site 85 (84)
Multiple sites 16 (16)
LDH Normal 77 (76)
Abnormal 24 (24)
β2-MG Normal 50 (50)
Abnormal 51 (50)
Hypoalbuminemia No 76 (75)
Yes 25 (25)
Anemia No 56 (55)
Yes 45 (45)
Site of origin Gastric 48 (47)




Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFS
β2-MG β2-microglobulinobstruction or intussusceptions (10 cases, 10 %), diar-
rhea (3 cases, 3 %), abdominal mass (6 cases, 6 %), and
perforation (2 cases, 2 %).
According to Ann Arbor staging with Musshoff modifi-
cation, all the patients had localized disease (Ie to IIe2)
with ECOG ≤2. Forty-two cases (44 %) presented with B
symptoms. Multiple extranodal involvement and elevated
serum LDH level were observed in 16 patients (16 %) and
24 patients (24 %), respectively. Fifty-one cases (50 %) had
elevated β2-microglobulin (β2-MG), 25 cases (25 %) had
hypoalbuminemia, and 45 cases (45 %) had anemia at
diagnosis.
As for the sites of origin, the most frequent site was
the stomach (gastric group; 48 cases, 48 %), followed by
the duodenum and small bowel (17 cases, 17 %), ileoce-
cal (16 cases, 15 %), and colorectal groups (15 cases,
15 %). The remaining 5 (5 %) patients (combined group)
had both gastric and intestinal involvement.
Surgical approaches and chemotherapy
Surgical modalities included radical surgery and allevia-
tive surgery (74 and 27 cases, respectively). Of the 74 pa-
tients who underwent radical surgery, 9 cases received
surgery alone, and the remaining 65 cases were treated
with chemotherapy alone, or combined with RituximabPG-DLBCL
5-year RFS P value 5-year OS P value
90.2 ± 4.2 % 0.040 91.8 ± 3.9 % 0.037
69.2 ± 9.3 % 67.0 ± 9.8 %
89.1 ± 4.6 % 0.244 90.7 ± 4.4 % 0.234
75.4 ± 7.6 % 74.1 ± 8.0 %
79.1 ± 6.2 0.190 79.7 ± 6.5 % 0.193
88.2 ± 5.6 % 87.6 ± 5.8 %
87.2 ± 4.3 % 0.040 87.8 ± 4.4 % 0.018
66.0 ± 12.4 % 63.6 ± 13.2 %
89.0 ± 4.3 % 0.011 90.9 ± 4.0 % 0.009
63.9 ± 11.0 % 63.6 ± 11.1 %
94.1 ± 4.1 % 0.034 93.2 ± 4.7 % 0.025
74.4 ± 6.7 % 75.9 ± 6.7 %
87.5 ± 4.4 % 0.036 88.3 ± 4.6 % 0.025
70.3 ± 10.3 % 67.9 ± 11.0 %
89.3 ± 4.5 % 0.144 91.1 ± 4.3 % 0.129
73.8 ± 8.1 % 71.8 ± 8.6 %
90.6 ± 5.2 % 0.012 92.8 ± 5.0 % 0.008
74.0 ± 13.2 % 70.7 ± 14.3 %
86.7 ± 8.8 % 86.7 ± 8.8 %
84.0 ± 10.6 % 82.1 ± 11.7 %
40.0 ± 21.9 % 40.0 ± 21.9 %
relapse-free survival, OS overall survival, LDH lactate dehydrogenase,
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found in the 27 patients who underwent alleviative sur-
gery (3, 8, and 16 cases, respectively, Table 1).Pathological characteristics
Detailed pathological features of the tumors were available
from operation (Table 2). Macroscopically, 12 tumors
(12 %) were classified as ulcerative type, 18 (18 %) as dif-
fuse type, and 71 (70 %) as massive type. Microscopically,
the depth of invasion were limited to mucosa/submucosa
(0), muscularis propria/subserosa (40, 40 %), beyond ser-
osa (visceral peritoneum) without invasion of adjacent
structures (43, 42 %), and involvement of adjacent struc-
tures or organs (18, 18 %). Involvement of regional lymph
node and adjacent tissue were present in 53 and 22 pa-
tients (52 and 22 %, respectively). The high level (>75 %)
of Ki-67 antigen was detected in the biopsy specimens of
25 cases (25 %). Bcl-2 expression was positive in 48 of the
101 patients (48 %).Treatment outcome
The overall CR, PR, and SD/PD rate were 73, 15, and
12 %, respectively. The median follow-up time was
23 months (ranged 1 to 115 months). Overall, the 5-year
RFS and OS rates were 82.5 ± 4.5 % and 83.9 ± 4.4 %, with
median RFS and OS at 43.3 and 49.6 months, respectively.
By univariate analysis, the clinical characteristics sig-
nificantly correlated with poor RFS and OS in the pa-
tients who received surgery were age older than 60 years
old, the presence of multiple extranodal involvement, ele-
vated serum LDH level and β2-MG, and decreased serumTable 2 Pathological features of patients with localized PG-DLBCL
Characteristics
Tumor morphology Ulcerative type
Diffuse type
Massive type
Depth of invasion Mucosa/submucosa
Muscularis propria/subserosa
Beyond serosa (visceral peritoneum) without
invasion of adjacent structures













Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFSalbumin (Table 1). Regarding pathological parameters,
adverse prognostic factors included invasion depth be-
yond serosa, involvement of regional lymph nodes or ad-
jacent tissue, high level of Ki-67, and Bcl-2 expression
(Table 2).
Gastric, duodenum and small bowel, ileocecal, and colo-
rectal group showed a higher survival rate than those with
multiple sites involved (Table 1). To determine the role of
surgery in the treatment of localized PG-DLBCL, we
included 49 patients who received chemotherapy alone as
control. As showed in Additional file 1: Table S1, no
significant difference of clinical characteristics and Ri-
tuximab treatment was observed between the patients
with surgery or those with chemotherapy alone. Surgery
did not prolong the survival rate of localized PG-
DLBCL patients, when compared with chemotherapy
alone. However, in the patients without Rituximab
treatment, mostly due to active infection of hepatitis B
virus, the survival rate showed longer RFS and OS in
cases who received radical surgery than those with alle-
viative surgery (RFS, 88.5 ± 4.4 % vs 69.5 ± 9.7 %; OS,
87.7 ± 4.8 % vs 72.3 ± 9.7 %, both P = 0.004). Addition of
Rituximab significantly improved the survival of the
patients who received alleviative surgery and chemo-
therapy (RFS, 92.9 ± 6.9 % vs 58.3 ± 18.6 %, P = 0.002;
OS, 91.7 ± 8.0 % vs 71.4 ± 17.1 %, P = 0.001), instead of
those who received radical surgery and chemotherapy
(RFS, 93.8 ± 4.3 % vs 88.2 ± 7.8 %, P = 0.302; OS, 93.3 ±
4.6 % vs 88.2 ± 7.8 %, P = 0.333, Table 3).
By multivariate analysis, the significant independent
prognostic factors for poor RFS and OS was multiple
gastrointestinal involvement.N (%) 5-year RFS P value 5-year OS P value
12 (12) 87.5 ± 11.7 % 0.251 87.5 ± 11.7 % 0.244
18 (18) 68.0 ± 12.0 % 66.7 ± 12.4 %
71 (70) 86.9 ± 4.7 % 88.1 ± 4.6 %
0 – 0.022 – 0.029
40 (40) 95.8 ± 4.1 % 94.7 ± 5.1 %
43 (42) 71.3 ± 8.1 % 73.7 ± 8.0 %
18 (18) 81.1 ± 9.9 % 80.4 ± 10.2 %
48 (48) 90.8 ± 5.1 % 0.038 89.4 ± 6.0 % 0.048
53 (52) 75.8 ± 6.7 % 77.8 ± 6.5 %
79 (78) 87.8 ± 4.4 % 0.024 86.5 ± 4.8 % 0.028
22 (22) 69.4 ± 10.5 % 73.6 ± 10.2 %
76 (75) 90.1 ± 3.8 % <0.001 91.3 ± 3.8 % <0.001
25 (25) 52.6 ± 14.4 % 48.0 ± 14.5 %
53 (52) 97.8 ± 2.2 % <0.001 97.6 ± 2.4 % <0.001
48 (48) 65.8 ± 8.2 % 65.8 ± 8.7 %
relapse-free survival, OS overall survival
Table 3 Treatment modalities of patients with localized PG-DLBCL
Treatment N 5-year RFS P value 5-year OS P value
Radical surgery 74 88.5 ± 4.4 % 0.004 87.7 ± 4.8 % 0.004
Alleviate surgery 27 69.5 ± 9.7 % 72.3 ± 9.7 %
Radical surgery and chemotherapy with Rituximab 44 93.8 ± 4.3 % 0.302 93.3 ± 4.6 % 0.333
Radical surgery and chemotherapy without Rituximab 21 88.2 ± 7.8 % 88.2 ± 7.8 %
Alleviate surgery and chemotherapy with Rituximab 16 92.9 ± 6.9 % 0.002 91.7 ± 8.0 % 0.001
Alleviate surgery and chemotherapy without Rituximab 8 58.3 ± 18.6 % 71.4 ± 17.1 %
Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFS relapse-free survival, OS overall survival
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As illustrated in Figs. 1 and 2, the staging systems varied
from each other for defining specific risk subgroups.
Ann Arbor staging with Musshoff modification could
not further stratify the early-stage patients into different
stages (stage I and stage II) (I, 5-year RFS, 86.8 ± 5.1 %;
5-year OS, 87.6 ± 5.3 % vs II, 5-year RFS, 77.9 ± 7.4 %; 5-
year OS, 76.9 % ± 7.7 %, P = 0.423 and P = 0.428, respect-
ively). IPI was able to define specific risk subgroups
(low/low–intermediate (L–I)-risk and intermediate–highFig. 1 The RFS and OS curve according to Ann Arbor stage modified by M
survival (OS) curves according to Ann Arbor stage modified by Musshoff (a
specific risk subgroups of patients with localized PG-DLBCL to some extent(I–H)/high-risk), but there was no prognostic difference
between the low-risk subgroup and the L–I-risk group
(5-year RFS and 5-year OS, P = 0.636 and P = 0.643, re-
spectively), or between the high–intermediate (H–I)-risk
subgroup and the high-risk group (5-year RFS and 5-
year OS, P = 0.694 and P = 0.725, respectively). Using
Lugano classification, the patients with advanced stage
(IIE) had significantly shorter survival time than those
with early stage (I and II) (IIE, 5-year RFS, 71.1 ± 11.0 %;
5-year OS, 76.0 ± 10.5 % vs I and II, 5-year RFS, 86.5 ±usshoff (a) and IPI score (b). The relapse-free survival (RFS) and overall
) and IPI score (b) show that these staging systems could define
Fig. 2 The RFS and OS curves according to Lugano classification (a) and Paris staging system (b–d). The relapse-free survival (RFS) and overall
survival (OS) curves according to Lugano classification (a) and Paris staging system (b–d) show that these staging systems could define specific
risk subgroups of patients with localized PG-DLBCL to some extent
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respectively). Using Paris staging system, the patients in
T3 and T4 showed no significant survival difference
(T3, 5-year RFS, 71.3 ± 8.1 %; 5-year OS, 73.7 ± 8.0 % vs
T4, 5-year RFS, 81.1 ± 9.9 %; 5-year OS, 80.4 ± 10.2 %,
P = 0.661 and P = 0.695, respectively) (Table 4). Of note,
according to IPI, Lugano early stage was grouped to IPI
0–2 (72 patients) and IPI 3–5 (10 patients) (Fig. 3). The
latter had similar RFS and OS of the cases with Lugano
late stage (P = 0.960 and P = 0.870, respectively). Thus,
combination of clinical and pathological staging system
was more efficient in classifying PG-DLBCL patients.
Discussion
PG-DLBCL represents the most common subtype of
extranodal lymphoma, mainly involved in stomach and
bowl [19]. Comparable to previous studies in Western
and Asian countries [20–26], clinical parameters associ-
ated with deteriorated patient status (older age and hy-
poalbuminemia) as well as increased tumor burden
(multiple extranodal and gastrointestinal involvement,
elevated LDH, and β2-MG) were important factors in-
dicating poor prognosis. Among all these univariate
prognostic factors, multiple gastrointestinal involve-
ment was independently related to adverse outcome of
the patients. With the development of endosonography,
radiological examination and PET-CT, patients withmultiple gastrointestinal involvement could be easily
distinguished nowadays. Also, pathological parameters
negatively correlated with disease prognosis were iden-
tified, including tumor infiltration and involvement of
regional lymph nodes, adjacent structures or organs,
high Ki-67, and Bcl-2 expression. As previously re-
ported, Ki-67 reflects high proliferation index and Bcl-2
is an important anti-apoptotic protein [27, 28], both of
which correlate with the aggressive course in patients
with DLBCL. Therefore, in addition to clinical prognos-
ticators, pathological characteristics that are associated
with biological behavior of the tumors are meaningful
for appropriate prognostic settings of the patients with
PG-DLBCL.
Rituximab, a chimeric anti-CD20 antibody, is generally
applied to treat B cell lymphoma. Like nodal lymph-
omas, the survival of primary gastric B cell lymphoma
has been improved upon Rituximab treatment [29, 30].
Interestingly, the negative impact of alleviate surgery
could be overcome by Rituximab treatment. Meanwhile,
based on our data and the others [24, 31, 32], radical
surgery may be considered as a therapeutic modality to
patients unfit for Rituximab treatment (active infection
of hepatitis B virus, etc.).
Staging systems are important to provide adequate
treatment guidance. For the early stage of localized
PG-DLBCL patients, Ann Arbor staging with Musshoff
Table 4 Staging systems of patients with localized PG-DLBCL
Staging system Stage N (%) 5-year RFS P value 5-year OS P value
Ann Arbor staging with Musshoff modification I (Ie1–Ie2) 62 (61) 86.8 ± 5.1 % 0.423 87.6 ± 5.3 % 0.428
II (IIe1–IIe2) 39 (52) 77.9 ± 7.4 % 76.1 ± 7.7 %
IPI Low 65 (64) 89.4 ± 4.5 % 0.006 90.9 ± 4.4 % 0.004
L–I 19 (19) 93.8 ± 6.1 % 93.8 ± 6.1 %
H–I 4 (4) 56.3 ± 14.8 % 55.6 ± 14.9 %
High 13 (13) 50.0 ± 2.5 % 50.0 ± 2.5 %
Lugano classification Early stage (I–II) 82 (81) 86.5 ± 4.5 % 0.039 85.4 ± 4.9 % 0.044
Late stage (IIE) 19 (19) 71.1 ± 11.0 % 76.0 ± 10.5 %
Paris staging system T 1 0 – 0.022 – 0.029
2 40 (40) 95.8 ± 4.1 % 94.7 ± 5.1 %
3 43 (42) 71.3 ± 8.1 % 73.7 ± 8.0 %
4 18 (18) 81.1 ± 9.9 % 80.4 ± 10.2 %
N 0 48 (48) 93.5 ± 4.5 % <0.001 92.2 ± 5.4 % <0.001
1 51 (50) 75.0 ± 6.9 % 77.2 ± 6.7 %
2 2 (2) 50.0 ± 35.4 % 50.0 ± 35.4 %
3 0 – –
M 0 95 (94) 85.9 ± 4.2 % 0.018 86.2 ± 4.3 % 0.020
1 6 (6) 50.0 ± 20.4 % 50.0 ± 20.4 %
2 0 – –
Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFS relapse-free survival, OS overall survival, IPI International Prognostic Index,
L–I low–intermediate, H–I high–intermediate
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stead, IPI appeared more efficient in dividing the pa-
tients into two risk subgroups with distinct outcome,
but it was unable to separate the survival of patients
with low and L–I risks, as well as high and H–I risks
[28, 33, 34]. Lugano classification [12, 25], including
major pathological parameters like the depth of infil-
tration and infiltration of adjacent organs, also proved
efficient. Interestingly, our data showed that IPI in conjunc-
tion with Lugano classification could further improve their
capacity to discriminate the important risk subgroups.
Therefore, the combination of clinical and pathologicalFig. 3 The RFS and OS curves according to the combination of Lugano cla
(OS) curves according to combination of Lugano classification and IPI show
was more efficient in classifying PG-DLBCL patientsstaging systems is optimal to predict the prognosis of PG-
DLBCL.Conclusions
Non-surgical treatment becomes an optimal thera-
peutic modality for localized PG-DLBCL in the Rituxi-
mab era. Addition of Rituximab might overcome the
negative prognostic effect of alleviative surgery. The
combination of pathological staging system and clinical
system is optimal for prognosis prediction in patients
with PG-DLBCL.ssification and IPI. The relapse-free survival (RFS) and overall survival
s that the combination of clinical and pathological staging system
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Additional file 1: Table S1. Clinical characteristics and survival rate of
patients with localized PG-DLBCL. It shows the clinical characteristics and
Rituximab treatment between localized PG-DLBCL patients with surgery
and those with chemotherapy alone. (PDF 276 kb)
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